Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity.

BACKGROUND/AIMS Nonalcoholic steatohepatitis is an emerging clinical problem among the obese population. However, risk factors of progression to advanced forms of liver disease in this particular group of patients remain to be defined. METHODS The demographics and clinical and histologic features of 46 obese patients were evaluated. The intrahepatic immunological phenotype was assessed in all liver biopsy samples by immunohistochemistry. RESULTS Histologic findings of nonalcoholic steatohepatitis were observed in 69.5% of the obese population studied and significant fibrosis was evident in 41% of patients with nonalcoholic steatohepatitis. Age (p=0.003), degree of steatosis (p=0.000002), and grade of inflammation (p=0000) at liver biopsy were independent variables positively associated with fibrosis. Intrahepatic expression levels of several immunologic markers of inflammation as well as nitric oxide derivatives were significantly higher in the severe forms of nonalcoholic steatohepatitis than in the mildest forms. CONCLUSIONS Obese persons with higher age, with greater degrees of hepatic steatosis, and specially those with increased grades of intrahepatic inflammation have the greatest risk for progression to fibrotic liver disease. An oxidative stress-triggered intrahepatic inflammatory response appears to be important in the pathogenesis of nonalcoholic steatohepatitis in obesity.

[1]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[2]  D. Pessayre,et al.  Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.

[3]  C. Day,et al.  Non-alcoholic steatohepatitis: another disease of affluence , 1999, The Lancet.

[4]  C. Degott,et al.  Liver in obesity. , 1985, Gut.

[5]  C. Day,et al.  Hepatic steatosis: Innocent bystander or guilty party? , 1998, Hepatology.

[6]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.

[7]  C. Quesenberry,et al.  Obesity, health services use, and health care costs among members of a health maintenance organization. , 1998, Archives of internal medicine.

[8]  F. Sánchez‐Madrid,et al.  Tumor necrosis factor‐α production induced in T lymphocytes through the AIM/CD69 activation pathway , 1992 .

[9]  F. Gordon,et al.  Nonalcoholic Steatohepatitis , 1997, Annals of Internal Medicine.

[10]  M. Clemens,et al.  Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Ward,et al.  Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.

[12]  A Tremblay,et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.

[13]  Randall G. Lee,et al.  Nonalcoholic steatohepatitis: a study of 49 patients. , 1989, Human pathology.

[14]  D. Pessayre,et al.  Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. , 1996, Journal of hepatology.

[15]  E. Lara-Pezzi,et al.  Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. , 1998, The Journal of clinical investigation.

[16]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[17]  M. Clemens.  Nitric oxide in liver injury , 1999, Hepatology.

[18]  F. Sánchez‐Madrid,et al.  Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. , 1995, Gastroenterology.

[19]  C. Day,et al.  Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. , 1998, Journal of hepatology.

[20]  F. Sánchez‐Madrid,et al.  Involvement of the CD4 molecule in a post‐activation event on T cell proliferation , 1987, European journal of immunology.

[21]  N. Kaplowitz,et al.  Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. , 1995, Molecular pharmacology.

[22]  D. Chadwick,et al.  The origins and consequences of obesity , 1996 .

[23]  S. Friedman,et al.  Molecular regulation of hepatic fibrogenesis. , 1998, Journal of hepatology.

[24]  I. Wanless,et al.  Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.

[25]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[26]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[27]  B. Malissen,et al.  Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis‐inhibiting effect of 7 monoclonal antibodies , 1982, European journal of immunology.

[28]  M. Thun,et al.  The effect of age on the association between body-mass index and mortality. , 1998, The New England journal of medicine.

[29]  H. Sekihara,et al.  Augmented Production of Tumor Necrosis Factor-α in Obese Mice , 1995 .

[30]  M. Carroll,et al.  Overweight and obesity in the United States: prevalence and trends, 1960–1994 , 1998, International Journal of Obesity.

[31]  V. Carloni,et al.  Signal transduction in hepatic stellate cells. , 2008, Liver.

[32]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis. , 1996, The Medical clinics of North America.

[33]  C. Cabañas,et al.  Characterization of a CD11c-reactive monoclonal antibody (HC1/1) obtained by immunizing with phorbol ester differentiated U937 cells. , 1988, Hybridoma.

[34]  A. García-Sánchez,et al.  Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b. , 1993, Gastroenterology.

[35]  K. Ishak,et al.  Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. , 1988, Gastroenterology.

[36]  J. Beckman.  Oxidative damage and tyrosine nitration from peroxynitrite. , 1996, Chemical research in toxicology.

[37]  M. Fernández-Bermejo,et al.  Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients , 1998, Hepatology.

[38]  J. Bartolomé,et al.  Hepatitis B virus X protein transactivates the inducible nitric oxide synthase promoter , 1999, Hepatology.

[39]  J. Wilding,et al.  Science, medicine, and the future: Obesity treatment , 1997, BMJ.

[40]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[41]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[42]  J. D. de Vries,et al.  Antigen‐specific cytotoxic T cell and antigen‐specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3 , 1985, European journal of immunology.

[43]  Michael Loran Dustin,et al.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.

[44]  G. Bray.  Obesity: a time bomb to be defused , 1998, The Lancet.

[45]  G. Bray.  Coherent, preventive and management strategies for obesity. , 2007, Ciba Foundation symposium.

[46]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[47]  C. García-Monzón,et al.  Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological severity of liver disease. , 2000, Journal of hepatology.

[48]  K. Ishak,et al.  ALCOHOL-LIKE DISEASE IN NONALCOHOLICS , 1988 .

[49]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[50]  M. Ingelman-Sundberg,et al.  Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis , 1998, Hepatology.

[51]  F. Sánchez‐Madrid,et al.  Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes , 1988, The Journal of experimental medicine.

[52]  R. Novak,et al.  Effects of fatty acids and ketone bodies on cytochromes P450 2B, 4A, and 2E1 expression in primary cultured rat hepatocytes. , 1997, Archives of biochemistry and biophysics.

[53]  H. Sekihara,et al.  Augmented production of tumor necrosis factor-alpha in obese mice. , 1995, Clinical immunology and immunopathology.

[54]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.